TABLE 1

A comparison of human doses of selected hallucinogens with their potency using drug discrimination tests in LSD-trained rats

Where available, K_i values for cloned human 5-HT_2A and 5-HT_2C receptors are also listed for comparison. Compounds are ranked by relative human potency. Reproduced by permission of Elsevier from Nichols (2004).

Drug^{^a}	K_i for5-HT_2A^{^b}	K_i for5-HT_2C^{^b}	DD ED₅₀^{^c}	Potency Relative to LSD (Rat DD)	Human Dose^{^d}	Potency Relative to LSD (Human)
	nM		μM/kg		mg
EthLAD	—	—	0.02	185	0.04–0.15	140
AllyLAD	—	—	0.013	285	0.08–0.16	110
LSD	2–4	3–6	0.037	100	0.06–0.20	100
ProLAD	—	—	0.037	100	0.10–0.20	90
DOB	0.6	1.3	1.06	2.3	1–3	7
DOI	0.7	2.4	0.28	9.2	1.5–3	6
DOM	19	ND	0.89	3.3	3–10	2
Psilocin	15–25	10	1.0	2.6	10–15	1
DMCPA	ND	ND	0.66	4.5	15–20	0.7
MEM	73	124	12	0.2	20–50	0.4
MMDA-2	ND	ND	7	0.4	25–50	0.4
Mescaline	550	300	34	0.08	200–400	0.04

AllyLAD, N-allyl-N(6)-norLSD; DD, drug discrimination; DMCPA, (±)-trans-2,5-dimethoxy-4-methylphenylcyclopropylamine; EthLAD, N-ethyl-N(6)-norLSD; MEM, (±)-2,5-dimethoxy-4-ethoxyamphetamine; MMDA-2, (±)-2-methoxy-4,5-methylenedioxyamphetamine; ProLAD, N-n-propyl-N(6)-norLSD.
↵^a Drug abbreviations are from Shulgin and Shulgin (1991, 1997).
↵^b Affinity of phenethylamines in cloned receptors taken from Nelson et al. (1999); mescaline affinity is from Monte et al. (1997).
↵^c Drug discrimination data from Blair et al. (2000), Hoffman and Nichols (1985), Monte et al. (1997), and Nichols et al. (1984a,b, 1986, 1991).
↵^dAveraged dose range from Shulgin & Shulgin (1991, 1997) (LSD = 100).